All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-07-24T14:19:38.000Z

Interim data from the phase I/II study on BNZ-1 in patients with refractory cutaneous T-cell lymphoma

Jul 24, 2020
Share:

Bookmark this article

On July 20, 2020, positive interim clinical data from the phase I/II study of BNZ-1 in patients with refractory cutaneous T-cell lymphoma (rCTCL) were announced.

BNZ-1 is a selective multi-cytokine inhibitor targeting interleukin (IL)-2, IL-9, and IL-15, which has demonstrated a favorable safety profile in two phase I studies in healthy volunteers. A phase I/II dose-escalation study (NCT03239392) is currently investigating the safety and activity of BNZ-1 in patients with rCTCL.

Patients with rCTCL, who had failed standard of care and other available treatment options, were treated with BNZ-1 across four different doses of 0.5, 1, 2, and 4 mg/kg for intravenous weekly dosing. The primary endpoint was overall safety after 4 weeks. There was a 3-month treatment extension to further evaluate the safety and efficacy. BNZ-1 was well tolerated with no dose limiting toxicities. The 2 mg/kg cohort included 19 patients with rCTCL, who had failed a median of seven prior skin-directed and systemic therapies, and demonstrated a clinical response, with

• over 80% of patients showing some improvement in tumor burden, assessed by the modified severity-weighted assessment tool (mSWAT) score

• about half achieving a partial response in the mSWAT score, and 5% achieving a complete response

• a mean duration of response of 277 days (9.2 months) in responding patients at the time of the data cutoff

Based on the outcomes of the phase II study, a phase III study could start in the first half of 2021.

  1. Bioniz Therapeutics. Bioniz announces positive efficacy and safety data for BNZ-1 from interim analysis of phase 1/2 study in cutaneous T-cell lymphoma. https://bioniz.com/bioniz-announces-positive-efficacy-and-safety-data-for-bnz-1-from-interim-analysis-of-phase-1-2-study-in-cutaneous-t-cell-lymphoma/. Published Jul 20, 2020. Accessed Jul 22, 2020.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox